Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Tumors.

NCT05976828 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT05976828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Tumors.
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 14, 2024
Completion date
August 14, 2033
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related carcinoma